Sonata Therapeutics Presents Data Supporting its Network Medicines™ Approach at SITC 2023

- Data showcase efficacy of Sonata’s SNT-3010912, SNT-20109 and SNT-101 programs in tumor models, demonstrating broad potential of Network Medicines to modulate all key cell types in tumor microenvironment -

WATERTOWN, Mass.--(BUSINESS WIRE)--Sonata Therapeutics, Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, will present three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The posters highlight Sonata’s proprietary Intrinsic Antigen Release Technology (iART) and two of the company’s oncology programs, all of which demonstrated in vivo efficacy in a variety of tumor models.

Network Medicines are drugs designed to modulate all the key cell types in networks of multifactorial diseases, thereby to halt or potentially reverse damage caused by such diseases. The majority of medicines are designed to disrupt or enhance single pathways in order to stop disease progression, but this approach often requires additional medications that target a different pathway, or combination therapy, to prevent drug resistance or drive response. In contrast, Sonata’s Network Medicines target pathways that change the complete dynamics of multifactorial diseases, resulting in more durable therapeutics and potentially better outcomes for patients.

Poster presentation details:

Title: Sonata’s Proprietary Intrinsic Antigen Release Technology (iART) Drives In Situ Generation of Potent Anti-Tumor Immunity Across Warm and Cold Tumor Models
Date/Time: Friday, November 3, 2023, 12:00pm-1:30pm and 5:10pm-6:40pm PT
Abstract Number: 1403-B

Key takeaways:

• Highlights the efficacy of SNT-3010912, Sonata’s proprietary iART, delivered as an mRNA payload across both warm and cold tumor models.
• Delivered intratumorally, SNT-3010912 induced a state-of-the-art form of enhanced immunogenic antigen release.
• Demonstrated durable in vivo efficacy in both models, with nearly complete tumor growth inhibition and >80% complete response when delivered to warm tumor models and prolonged tumor growth inhibition in the majority of cold tumor models.
• Efficacy across a variety of tumor models highlights the distinctive capacity of Sonata’s iART to drive protective immunity across a spectrum of tumor immune landscapes.

Title: SNT-20109 Induces Protective Immunity in the Murine Syngeneic Tumor Cell Line, CT26: A Dual Approach of Direct Cytotoxicity and Defined Immune Activation
Date/Time: Friday, November 3, 2023, 12:00pm-1:30pm and 5:10pm-6:40pm PT
Abstract Number: 1387

Key takeaways:

• Highlights the use of SNT-20109, one of Sonata’s lead oncology programs, in an engineered murine tumor model.
• Demonstrated durable in vivo efficacy, inducing an innovative form of enhanced immunogenic cell death (ICD) that has never been characterized and robust production of pro-inflammatory cytokines and chemokines with known antitumoral effects not typically seen following ICD.
• Mice treated with SNT-20109 showed significant tumor growth inhibition, and nine of the ten subjects showed complete regression, indicating it could drive a unique immunological cascade with broad potential for future cancer treatment investigations.

Title: Exploring Novel Ferroptosis Inducer as a Promising Strategy for Sarcoma Treatment
Date/Time: Saturday, November 4, 2023, 11:55am-1:25pm and 7:00pm-8:30pm PT
Abstract Number: 1442

Key takeaways:

• Highlights the use of SNT-101 as a novel ferroptosis inducer for the potential treatment of sarcomas in human and murine cell lines.
• SNT-101 potently reduced viability, and induced cell death and lipid peroxidation in both cell lines, resulting in significant target exposure and tumor growth inhibition.
• Efficacy was benchmarked against pazopanib, showing that SNT-101 had improved efficacy compared to pazopanib.
• Data demonstrate that ferroptosis induction is a promising strategy for the treatment of sarcomas, supporting Sonata’s continued investigation in syngeneic mouse models.

“Sonata’s poster presentations showcase exciting early data for our Network Medicines, highlighting how this new therapeutic class could dramatically improve outcomes in the field of immuno-oncology,” said Volker Herrmann, M.D., MBA, Chief Executive Officer and President of Sonata Therapeutics. “Through our proprietary platform, Sonata is generating Network Medicines that move beyond the current immunotherapeutic paradigm. While current therapeutics are typically designed to address only one or two pathways, Network Medicines are intentionally designed to modulate all key pathways that drive disease.”

The first two posters will be presented by Ryan Shaler, Ph.D., in Exhibit Halls A and B1 of the San Diego Convention Center on Friday, November 3. The third poster will be presented by Maria Cristina Munteanu, Ph.D., on the Ground Level of Exhibit Hall B in the San Diego Convention Center on Saturday, November 4. More information on the presentations can be found at the SITC website.

Satellite Symposium
Sonata’s Chief Scientific Officer Francesco Marincola, M.D., will also co-chair a SITC satellite symposium, “Synthetic Biology – Cell Therapy for Patients with Solid Cancer,” on Friday, November 3 from 12:15-1:15 pm PT in Room 11AB of the conference venue. The symposium, sponsored by the Champalimaud Foundation, will highlight real-world challenges, outline solutions and foster collaborations to achieve the ultimate goal of significantly improving the survival of patients with cancer through synthetic biology.

About Sonata Therapeutics
Sonata Therapeutics is creating a new class of Network Medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. We are building a diverse portfolio of promising medicines for oncology and exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. www.sonatatx.com

Media:
MacDougall Advisors
Carolyn Noyes
cnoyes@macdougall.bio
781-235-3060